News | November 27, 2021
Fifty-five manufacturers selected for Pharma PLI sector
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
